Citadel Advisors’s Altamira Therapeutics Ltd CYTO Stock Holding History

Citadel Advisors’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-98	Closed	-$11K	–	15696
2022 Q3	$11K	Sell	98 -2	-2%	-$332	﹤0.01%	12261
2022 Q2	$19K	Sell	100 -151	-60%	-$48.7K	﹤0.01%	12433
2022 Q1	$110K	Buy	251 +133	+113%	+$64.2K	﹤0.01%	12187
2021 Q4	$85K	Buy	+118	New	+$79.1K	﹤0.01%	12883
2021 Q3	–	Sell	-25	Closed	-$36K	–	14940
2021 Q2	$36K	Sell	25 -1	-4%	-$1.37K	﹤0.01%	13448
2021 Q1	$36K	Buy	+26	New	+$34.8K	﹤0.01%	13000

Other funds holding CYTO

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's CYTO Position: Q4 2024 in Review

Citadel Advisors sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2024, closing a stake of 14,802 shares — an estimated $9.35K sold.

Citadel Advisors first reported a position in CYTO in Q1 2018 and held it in 10 quarters. The position peaked at $159K in Q1 2021. 2 funds tracked by Wall St. Rank hold CYTO as of Q4 2024.

Citadel Advisors reported no remaining Altamira Therapeutics Ltd position as of Q4 2024 after selling out during the quarter.
Citadel Advisors sold 14,802 Altamira Therapeutics Ltd shares in Q4 2024, an estimated $9.35K.
Citadel Advisors first reported a position in Altamira Therapeutics Ltd in Q1 2018 and held it in 10 quarters.
Citadel Advisors's Altamira Therapeutics Ltd position peaked at $159K in Q1 2021.
2 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.